(NE)-N-[5-(4-chlorophenyl)-4-methyl-1,3-oxazolidin-2-ylidene]nitramide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (NE)-N-[5-(4-chlorophenyl)-4-methyl-1,3-oxazolidin-2-ylidene]nitramide
• 化学式: C10H10ClN3O3
• 分子量: 255.66
• InChiKey: NXHDONWAEGBETK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  79.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Oxa(thia)zolidine derivative and anti-inflammatory drug
  申请人：——

  公开号：US20030199479A1

  公开（公告）日：2003-10-23

  The present invention provides medicinal compositions characterized by containing as the active ingredient either a compound represented by a general formula (1) or a pharmaceutically acceptable composite thereof, 1 [wherein X represents oxygen or sulfur; R 1 represents hydrogen, C 1-4 alkyl, etc.; R 2 represents, e.g., phenyl optionally substituted by A 1 ; R 3 represents, e.g., hydrogen, C 1-4 alkyl optionally substituted by A 2 , or a group represented by either one of the following formulae; 2 R represents oxygen, sulfur, or a group represented by a formula (N—G)], in particular, inhibitors of phospholipase A(2) activity; use of the compositions; and compounds represented by a general formula (1-1); 3 wherein X, R 1 , R 2 , R 3 and G 1 are the same as defined in the description.

  本发明提供了药物组合物，其特征在于含有以下通用式（1）所代表的化合物或其药学上可接受的复合物作为活性成分：其中X代表氧或硫；R1代表氢，C1-4烷基等；R2代表苯基，可选择地由A1取代；R3代表氢，C1-4烷基，可选择地由A2取代，或者由以下任一式子所代表的基团；R代表氧、硫，或者由式（N—G）所代表的基团，特别是磷脂酶A（2）活性的抑制剂；以及所述组合物的使用；以及通用式（1-1）所代表的化合物；其中X、R1、R2、R3和G1的定义与描述中的相同。
• Oxa(thia)zolidine derivatives and anti-inflammatory drugs
  申请人：Nippon Soda Co. Ltd.

  公开号：US20040220244A1

  公开（公告）日：2004-11-04

  The present invention provides medicinal compositions characterized by containing as the active ingredient either a compound represented by a general formula (1) or a pharmaceutically acceptable composite thereof, 1 wherein X represents oxygen or sulfur; R 1 represents hydrogen, C 1-4 alkyl, etc.; R 2 represents, e.g., phenyl optionally substituted by A 1 ; R 3 represents, e.g., hydrogen, C 1-4 alkyl optionally substituted by A 2 , or a group represented by either one of the following formulae; 2 R represents oxygen, sulfur, or a group represented by a formula (N-G)], in particular, inhibitor of phospholipase A(2) activity; use of the composition; and compound represented by a general formula (1-1); 3 wherein X, R 1 , R 2 , R 3 and G 1 are the same as defined in the description.

  本发明提供了药物组合物，其特征在于包含以下化合物或其药学上可接受的复合物作为活性成分：式（1）所代表的化合物，其中X代表氧或硫；R1代表氢、C1-4烷基等；R2代表苯基，该苯基可选择由A1取代；R3代表氢、C1-4烷基，可选择由A2取代，或者由以下任一式子所代表的基团：2R代表氧、硫，或由式（N-G）所代表的基团，特别是磷脂酶A(2)活性抑制剂。本发明还涉及该组合物的用途以及式（1-1）所代表的化合物，其中X、R1、R2、R3和G1如上所述。
• OXA(THIA)ZOLIDINE DERIVATIVE AND ANTI-INFLAMMATORY DRUG
  申请人：NIPPON SODA CO., LTD.

  公开号：EP1277743A1

  公开（公告）日：2003-01-22

  The present invention provides medicinal compositions characterized by containing as the active ingredient either a compound represented by a general formula (1) or a pharmaceutically acceptable composite thereof,    [wherein X represents oxygen or sulfur; R1 represents hydrogen, C1-4 alkyl, etc.; R2 represents, e.g., phenyl optionally substituted by A1; R3 represents, e.g., hydrogen, C1-4 alkyl optionally substituted by A2, or a group represented by either one of the following formulae;    R represents oxygen, sulfur, or a group represented by a formula (N-G)], in particular, inhibitor of phospholipase A(2) activity; use of the composition; and compound represented by a general formula (1-1); wherein X, R1, R2, R3 and G1 are the same as defined in the description.

  本发明提供了药物组合物，其特征是含有通式(1)代表的化合物或其药学上可接受的复合物作为活性成分、 [其中X代表氧或硫；R1代表氢、C1-4烷基等；R2代表例如被A1任选取代的苯基；R3代表例如氢、被A2任选取代的C1-4烷基或由下式之一代表的基团； R代表氧、硫或由式（N-G）代表的基团]，特别是磷脂酶 A(2)活性抑制剂；组合物的用途；以及由通式（1-1）代表的化合物； 其中 X、R1、R2、R3 和 G1 与说明中定义的相同。
• US6762200B2
  申请人：——

  公开号：US6762200B2

  公开（公告）日：2004-07-13